FDA approves Roche's Wilserdly for resistant breast cancer
The FDA cleared Roche's Wilserdly on Monday for HR-positive, HER2-negative advanced breast cancer that has picked up an ESR1 mutation. The oral drug, also known as giredestrant, could become Roche's best-selling product ever, the company has said. The evERA trial showed it delayed tumor progression.
- 7 sources report it: statnews.com, msn.com, finance.yahoo.com, curetoday.com and 3 more.
- The source published it on Nov 16, 2026 at 12:57 PM.
Nothing open. Every check passed.
The Food and Drug Administration approved Wilserdly, also called giredestrant, on Monday. The Roche drug is an oral treatment cleared for patients with HR-positive, HER2-negative advanced breast cancer that has acquired a mutation in the ESR1 gene — a change that signals a tumor is turning resistant to standard therapies. Roche has said the medicine could become its top-selling product ever.
The evERA trial showed Wilserdly extended the time before patients' tumors progressed. The drug works as a selective estrogen receptor degrader, or SERD.
For the Swiss company, the decision was one of the most important regulatory calls it had been awaiting. It also gives Roche another foothold in breast cancer, a field where its subsidiary Genentech built a storied history with Herceptin — even as Roche has fallen behind rival pharma companies in oncology in recent years.
TopicsFDA · Roche · Wilserdly · giredestrant · Genentech · Herceptin · evERA trial
Written by AI from verified reporting.

